Researcher Financial Conflicts Influence Flu Drug Studies
This article is for subscribers only.
Researchers with financial ties to flu drug companies more often reported positive findings in their studies of the treatments, a new analysis found.
Seven of eight studies that analyzed previous research and whose researchers had financial ties to the drug industry were considered favorable to the flu treatments, including Roche Holding AG’s Tamiflu and GlaxoSmithKline Plc’s Relenza, according to research today in the Annals of Internal Medicine. That compares with five favorable findings of 29 reviews from researchers who didn’t report similar financial conflicts of interest.